News

Treatment with the investigational therapy CST-103 increased blood flow to certain regions of the brains of people with Parkinson’s disease and mild cognitive impairment, results of a small clinical trial show. The type of increased blood flow that was seen “correlates with increased neuronal activity and cognitive benefit,” Gabriel…

An investigational therapy, ATH434 was able to reverse some gastrointestinal problems in a mouse model of Parkinson’s disease, according to its developer Alterity Therapeutics. “Practicing clinicians are well aware of the substantial impact that these symptoms have on the quality of life of individuals with Parkinson’s disease,” David Stamler,…

The active agent in Solace PS128, a probiotic sold by Oryx Biomedical, eased disease symptoms and improved life quality in 25 people with Parkinson’s disease given the supplement in a small, open-label clinical trial. “Solace PS128 is the result of more than 20 years of scientific research,” David…

Scientists from Northwestern University will use two grants — totaling $17.9 million — from the Aligning Science Across Parkinson’s (ASAP) initiative to study alterations in the brain that contribute to the development of Parkinson’s disease. Their research focuses on brain circuits, the specific populations of interconnected brain cells…

The death rate from Parkinson’s disease in the U.S. has gradually and significantly increased — by 63% — over two decades across all age groups, sexes, and racial and ethnic groups, according to a study based on nationwide mortality data. In the same period, men died twice as much…

A team of scientists from the University of Florida (UF) will use a $1.1 million grant to further their work on the use of artificial intelligence- or AI-powered medical research for predicting and diagnosing Parkinson’s disease while maintaining patient privacy. This grant, from the National Institutes for Health (NIH),…

ABBV-951, an under-the-skin formulation of levodopa/carbidopa, outperformed the standard oral therapy at controlling Parkinson’s symptoms in advanced disease patients in a Phase 3 clinical trial, top-line results show. “These data are promising and demonstrate positive results on a key endpoint used to assess efficacy of treatments for patients with…

Fascinate Therapeutics has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial evaluating KM-819 as a potential therapy for Parkinson’s disease, the company announced in a press release. Parkinson’s disease is characterized by the death and dysfunction…

The U.S. Food and Drug Administration has approved Insightec’s incision-free brain “surgery” technology — Exablate Neuro — for the treatment of motor symptoms in Parkinson’s disease patients. According to the company, the device is indicated to use in patients with moderate-to-severe motor complications, such as tremors, stiffness and uncontrolled, involuntary movement…

Those attending The Michael J. Fox Foundation’s (MJFF) “A Funny Thing Happened on the Way to Cure Parkinson’s” annual fundraiser got to hear from the organization’s founder, Michael J. Fox. Nearly 700 supporters converged on the Jazz at Lincoln Center in New York City recently to celebrate the…